Skip to Content

AstraZeneca COVID-19 Vaccine Trial Restarts

MONDAY, Sept. 14, 2020 -- Oxford University has announced that final-stage testing of a COVID-19 vaccine it is developing with drug maker AstraZeneca will restart following a pause last week after a serious side effect showed up in a volunteer.

"The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator … the trials will recommence in the U.K.," the university said in a statement released on Saturday. No further details were given on the results of the review.

Media reports have said the person who had the suspected adverse reaction had been volunteering in a trial based in the United Kingdom. The volunteer was diagnosed with transverse myelitis. The university said in large trials, "it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety." Globally, some 18,000 people have received the vaccine so far, the Associated Press reported.

The AstraZeneca vaccine is considered a front-runner among the dozens of COVID-19 vaccines in various stages of testing around the world, the AP reported.

AP News Article

© 2021 HealthDay. All rights reserved.

Read this next

Circulation of Respiratory Viruses Low During COVID-19 Pandemic

FRIDAY, July 23, 2021 -- Circulation of respiratory viruses, including influenza and respiratory syncytial virus, was low during the COVID-19 pandemic, according to research...

Vaccinations Start to Climb in States Hit Hard by Delta Variant

FRIDAY, July 23, 2021 -- In a sign that vaccine-hesitant Americans are starting to worry about the rapid spread of the highly infectious delta variant, vaccinations are beginning...

Black, Hispanic Communities Devastated by Loss Are Taking COVID-19 Safety Precautions

FRIDAY, July 23, 2021 -- Black and Hispanic community perspectives on COVID-19 mitigation behaviors and testing are informed by devastating experiences, yet vaccine skepticism...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.